BMJ  2008;336:418-419 (23 February), doi:10.1136/bmj.39491.469005.94

Feature

Drug Research

Balancing Big Pharma’s books

¹ Financial Times, London

With patents running out on their big earning products and recent scandals undermining their image, drug companies are under pressure. Andrew Jack reports on their problems

The first 150 words of the full text of this article appear below.

When business chief executives joined politicians and public officials gathered at the World Economic Forum in Davos last month, one group of industry leaders was noticeably under-represented: those from the pharmaceutical sector. Some regulars in previous years, such as Hank McKinnell, the outspoken former head of Pfizer, the world’s largest drug group, have lost their jobs. Others, like Richard Clark from Merck and Daniel Vasella from Novartis, pulled out at the last minute. The message was clear. At a time of investor dissatisfaction with their companies and employee disgruntlement at cutbacks, they would do better to stay in their headquarters and focus on internal problems rather than debate the broader issues of the world.

To many, it seems hard to believe that the drug industry - long spoilt by lavish revenues and little need for controls on spending - is in crisis. In fact, its current malaise is characterised by . . . [Full text of this article]

Illusion of plenty

Expiring patents

Burden of riches

Science outstrips medicine

Disappointing demand

Poor perception

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Rapid Responses:

Read all Rapid Responses

Trouble ahead for "Big Pharma"

Manthan D. Janodia, et al.
bmj.com, 24 Feb 2008 [Full text]

There is no right answer to the wrong question

Aubrey Blumsohn
bmj.com, 27 Feb 2008 [Full text]